Finally, the subcutaneous injection of the TLR3 agonist poly(I:C) during radiotherapy was found to not only activate tumor cell ferroptosis signaling but also enhance the abscopal effect, promote the DC-mediated presentation of tumor neoantigens, and increase the recruitment of activated CD8+ T cells to distant tumor tissues, thereby improving the radiosensitivity of HCC [49]. This evidence concerns the gene TLR3 and neoplasm.